

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10687783
Filing Date	2003-10-17
First Named Inventor	Heuser
Art Unit	3738
Examiner Name	Suzette Jaime J. Gherbi
Attorney Docket Number	HEU 309

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6536949		2003-03-25	Heuser	
	2	6582394		2003-06-24	Reiss et al.	
	3	6638268		2003-10-28	Niazi	
	4	6746479		2004-06-08	Ehr et al.	
	5	6830568		2004-12-14	Kesten et al.	
	6	6858038		2005-02-22	Heuser	
	7	7166088		2007-01-23	Heuser	
	8	7179250		2007-02-20	Heuser	

If you wish to add additional U.S. Patent citation information please click the Add button.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10687783		
		Filing Date		2003-10-17		
		First Named Inventor		Heuser		
		Art Unit		3738		
		Examiner Name		Suzette Jaime J. Gherbi		
		Attorney Docket Number		HEU 309		

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20010003161		2001-06-07	Vardi et al.	
	2	20050125011		2005-06-09	Spence et al.	
	3	20060047222		2006-03-02	Heuser	
	4	20060217799		2006-09-28	Mailander et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	EP1421970	EP		2004-05-26	Schur		<input type="checkbox"/>
	2	FR2753907	FR		1998-03-04	Boussignac et al.		<input checked="" type="checkbox"/>
	3	JP0003094773	JP		1991-04-19	Inaba et al.		<input checked="" type="checkbox"/>
	4	WO9640348	WO		1996-12-19	Ravenscroft et al.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10687783		
		Filing Date		2003-10-17		
		First Named Inventor		Heuser		
		Art Unit		3738		
		Examiner Name		Suzette Jaime J. Gherbi		
		Attorney Docket Number		HEU 309		

	5	WO9717101	WO		1997-05-15	Myler		<input type="checkbox"/>
	6	WO9811933	WO		1998-03-26	Ravenscroft et al.		<input type="checkbox"/>
	7	WO9913808	WO		1999-03-25	Wisselink		<input type="checkbox"/>
	8	WO9934749	WO		1999-07-15	Webster		<input type="checkbox"/>
	9	WO9936002	WO		1999-07-22	Vardi et al.		<input type="checkbox"/>
	10	WO0166038	WO		2001-03-02	Greenberg		<input type="checkbox"/>
	11	WO0596995	WO		2005-10-20	Andreas et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	English Abstract of JP0003094773 of Inaba et al.	<input type="checkbox"/>
	2	English Abstract of FR2753907 of Boussignac et al., from WO/98/14233 publication, from which FR2753907 claims priority.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10687783
		Filing Date	2003-10-17
		First Named Inventor	Heuser
		Art Unit	3738
		Examiner Name	Suzette Jaime J. Gherbi
		Attorney Docket Number	HEU 309

	3	BAFFOUR, M.S.C., R. et al. "An Angiographic Study of Ischemia as a Determinant of Neovascularization in Arteriovenous Reversal." <i>Surgery, Gynecology & Obstetrics</i> . January 1988. Pages 28-32. Vol. 166.	<input type="checkbox"/>
	4	BERNHEIM, M.D., BERTRAM. "Arteriovenous Anastomosis - Reversal of the Circulation - As a Preventative of Gangrene of the Extremities." <i>Arteriovenous Anastomosis</i> . Undated.	<input type="checkbox"/>
	5	BLAISDELL, M.D., WILLIAM, et al. "Revascularization of Severely Ischemic Extremities with an Arteriovenous Fistula." <i>American Journal of Surgery</i> . August 1966. Pages 166-174. Vol. 112.	<input type="checkbox"/>
	6	CUTTINO JR., JOHN, et al. "Collateral Vessel Formation: Isolation of a Transferrable Factor Promoting a Vascular Response." <i>Basic Research in Cardiology</i> . January 9, 1975. Pages 568-573. Vol. 70, No. 5.	<input type="checkbox"/>
	7	GERARD, M.D., DAVA, et al. "Acute Physiologic Effects of Arteriovenous Anastomosis and Fistula in Revascularizing the Ischemic Canine Hind Limb." <i>Surgery</i> . April 1981. Pages 485-493. Vol. 89, No. 4.	<input type="checkbox"/>
	8	GOLDSMITH, M.D., HARRY, et al. "Lipid Angiogenic Factor from Omentum." <i>JAMA</i> . October 19, 1984. Pages 2034-2036. Vol. 252, No. 15.	<input type="checkbox"/>
	9	HALSTEAD, M.D., ALBERT. "Arteriovenous Anastomosis in the Treatment of Gangrene in the Extremities." <i>Surgery, Gynecology and Obstetrics</i> . 1912. Pages 1-19. Vol. 16.	<input type="checkbox"/>
	10	HOWELL, M.D., MARCUS, et al. "Preliminary Results of Endovascular Abdominal Aortic Aneurysm Exclusion with the AneuRx Stent-Graft." <i>Journal of the American College of Cardiology</i> . 2001. Pages 1040-1048. Vol. 38, No. 4.	<input type="checkbox"/>
	11	JOHNSON & JOHNSON GATEWAY, LLC. "Chronic Total Occlusion (CTO) Technologies." http://www.jnjgateway.com/home.jhtml?loc=USENG&page=viewContent&contentId=09008b9881163810&parentId=09008b9881163810 . 2007. Printed January 17, 2007.	<input type="checkbox"/>
	12	KALMAR, M.D., GABOR, et al. "Radial Force and Wall Apposition of Balloon-expandable Vascular Stents in Eccentric Stenoses: An In Vitro Evaluation in a Curved Vessel Model." <i>Journal of Vascular and Interventional Radiology</i> . May 2002. Pages 499-508. Volume 13, No. 5.	<input type="checkbox"/>
	13	KUMAR, S., et al. "Angiogenesis Factor from Human Myocardial Infarcts." <i>The Lancet</i> . August 13, 1983. Pages 364-368.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10687783
		Filing Date	2003-10-17
		First Named Inventor	Heuser
		Art Unit	3738
		Examiner Name	Suzette Jaime J. Gherbi
		Attorney Docket Number	HEU 309

	14	MATOLO, M.D., NATHANIEL. "Use of an Arteriovenous Fistula for Treatment of the Severely Ischemic Extremity: Experimental Evaluation." Ann. Surg. November 1976. Pages 622-625. Vol. 184, No. 5.	<input type="checkbox"/>
	15	OESTERLE, et al. "An Embolization Containment Device." Catheterization and Cardiovascular Interventions. 1999. Pages 243-250. Vol. 47.	<input type="checkbox"/>
	16	ROBERTSON, M.D., ROY, et al. "Collateral Circulation in the Presence of Experimental Arteriovenous Fistula." Surgery. January 1950. Pages 1-16. Volume 27, No. 1.	<input type="checkbox"/>
	17	ROOT, M.D., HARLAN, et al. "Effects of an Arteriovenous Fistula on the Devascularized Limb." JAMA. February 22, 1965. Pages 109-112. Volume 191, No. 8.	<input type="checkbox"/>
	18	ROSSI, ANNE V. "510(k) Summary per 21 CFR 807.92 re BSC IQ Hydrophilic Guide Wire and Response Letter from Department of Health and Human Services." August 1, 2003.	<input type="checkbox"/>
	19	SHEIL, A.G.R. "Treatment of Critical Ischaemia of the Lower Limb by Venous Arterialization: an Interim Report." Br. J. Surg. 1977. Pages 197-199.	<input type="checkbox"/>
	20	SZILAGYI, M.D., EMERICK. "Femoral Arteriovenous Anastomosis in the Treatment of Occlusive Arterial Disease." A. M.A. Archives of Surgery. Undated.	<input type="checkbox"/>
	21	TERUMO MEDICAL CORPORATION. "Glidewire Hydrophilic Coated Guidewire Designed for Peripheral Applications." http://www.terumomedical.com/SubDepts.asp?myID=79 . 2002. Printed January 30, 2007.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10687783
	Filing Date		2003-10-17
	First Named Inventor		Heuser
	Art Unit		3738
	Examiner Name		Suzette Jaime J. Gherbi
	Attorney Docket Number		HEU 309

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/s/ Peter E. Heuser	Date (YYYY-MM-DD)	2007-05-31
Name/Print	Peter E. Heuser	Registration Number	27902

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.